Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|October 22, 2020
Dr. Kathleen Kieran discusses peer-reviewed authorship for women in urology
Author(s)Urology Times staff
Kieran discusses findings from a recent study published in the journal Urology.
Advertisement
In this interview, Kathleen Kieran, MD, MSc, MME, discusses findings from the recent Urology study, Gender differences in authorship in urology: a five-year review of publications in five high-impact journals, for which she served as senior author. Kieran is an associate professor of urology at the University of Washington, Seattle.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5